|

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

RECRUITINGSponsored by Northwestern University
Actively Recruiting
SponsorNorthwestern University
Started2020-10-01
Est. completion2027-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT04616131

Summary

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Biopsy or cytology proven adenocarcinoma of the pancreas
* No clinical evidence of metastatic disease on imaging
* Age 18 or older
* Receiving chemotherapy for non-metastatic pancreatic cancer

Exclusion Criteria:

* Biopsy proven metastatic disease

Conditions2

CancerPancreas Cancer

Locations3 sites

Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Donald Smith630-352-5360Donald.Smith3@nm.org
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60135
Donald Smith630-352-5360donald.smith3@nm.org
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
Akhil Chawla, MD630-352-5353Akhil.Chawla@nm.org

Find trials near these locations

All trials in Illinois

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.